Company intelligence / Profile preview
Hikma Pharmaceuticals
London, United Kingdomhikma.com ↗
- Ownership
- Public · HIK
- Employees
- ~8800
- Development stage
- Commercial
01
Overview
Hikma Pharmaceuticals plc operates as a leading global generic and specialty pharmaceutical company with a strong focus on injectables and oral generics. It has over $3 billion in annual revenue and more than $700 million in operating income as of FY2024. The company supplies over 800 products across North America, MENA and Europe. Its portfolio includes small molecule generics/branded drugs and biosimilars for major therapeutic areas such as oncology/cancer care and infectious diseases. Recent clinical/commercial highlights include the launch of biosimilar rituximab/trastuzumab in MENA through Celltrion partnerships; acquisition of Novugen’s FDA-approved ANDA for trametinib; exclusive licensing deals to bring innovative oncology treatments to the MENA region; continued expansion via acquisitions in Europe/MENA/US markets.[2][6]
- Therapeutic areas
- OncologyMetabolic DisordersCardiovascularNeurologyInfectious Diseases
- Modalities
- Small molecules (generics and branded generics)Biosimilars (e.g., rituximab, trastuzumab)[6]Injectables (sterile liquid, powder, lyophilized, cytotoxic products)[10]
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Celltrion Healthcare Co., Ltd. for biosimilars commercialization in MENA regionpharma& for innovative oncology licensingNovugen for ANDA acquisitionBoehringer Ingelheim asset acquisitions.Civica Rx supply partnerships.Group Purchasing Organisations/hospital networks.[2][6]
04
Financials
- Market cap
- $4.5B
- Total revenue
- $3.3B
- Enterprise value
- $6.2B
Beyond the preview
Go deeper on Hikma Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hikma Pharmaceuticals.